List of Excipients in Branded Drug 24 HOUR ALLERGY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Walgreens	24 HOUR ALLERGY	cetirizine hcl	0363-1219	FD&C YELLOW NO. 6
Walgreens	24 HOUR ALLERGY	cetirizine hcl	0363-1219	GELATIN
Walgreens	24 HOUR ALLERGY	cetirizine hcl	0363-1219	GLYCERIN

Generic Drugs Containing 24 HOUR ALLERGY

Company	Ingredient	NDC	Excipient
Meijer Distribution Inc	cetirizine hydrochloride	41250-458	FD&C BLUE NO. 1
Meijer Distribution Inc	cetirizine hydrochloride	41250-458	HYPROMELLOSE
Meijer Distribution Inc	cetirizine hydrochloride	41250-458	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in 24 HOUR ALLERGY?

# Of NDCs	Excipient
2	BUTYLATED HYDROXYTOLUENE
2	CELLULOSE, MICROCRYSTALLINE
2	CROSCARMELLOSE SODIUM

Excipient Strategy and Commercial Opportunities for 24 HOUR ALLERGY

Last updated: February 26, 2026

What are the key excipient considerations for 24 HOUR ALLERGY?

The formulation of 24 Hour Allergy primarily involves active ingredients such as cetirizine or loratadine. The excipients support stability, bioavailability, and patient compliance.

Common excipients include:

• Fillers: microcrystalline cellulose, lactose
• Disintegrants: croscarmellose sodium, sodium starch glycolate
• Flavoring agents: flavorings to improve palatability
• Preservatives: sodium benzoate, parabens
• Binders and lubricants: magnesium stearate, povidone

Formulation strategies

• Use excipients compatible with antihistamines to avoid stability issues.
• Incorporate taste-masking agents for oral solutions or dispersible forms.
• Select excipients that improve shelf life and reduce degradation risks.

What are the main commercial opportunities in excipient development?

Opportunities include:

• Enhanced bioavailability formulations: using lipophilic excipients or solubilizers to improve onset.
• Reduced excipient toxicity: developing excipients with improved safety profiles.
• Patient-centric delivery: creating dispersible tablets, liquid formulations, or dissolvable strips requiring specific excipients.
• Regulatory compliance: sourcing excipients with established safety data to accelerate approval.

Market drivers

• Increasing demand for fast-acting, convenient allergy medications.
• Growing preference toward pediatric and geriatric formulations.
• Regulatory emphasis on excipient safety and transparency.

Competitive landscape

• Larger pharma firms focus on proprietary excipient complexes.
• Specialty excipient manufacturers develop tailored solutions.
• Generic manufacturers optimize excipient compositions for cost efficiency.

How do regulatory policies affect excipient use?

• The U.S. FDA and EMA require detailed excipient safety data.
• Novel excipients face higher approval requirements.
• Labeling regulations mandate disclosure of all excipients, influencing formulation choices.

What are the innovation areas for excipients in allergy drugs?

• Use of natural excipients to align with clean-label trends.
• Development of multifunctional excipients that combine disintegrant, binder, and flavoring roles.
• Implementation of advanced excipient technology like film coatings for taste masking and controlled release.

What are the risks associated with excipient choices?

• Potential allergic reactions, especially in sensitive populations.
• Stability issues leading to reduced shelf life.
• Cost implications of using high-quality or proprietary excipients.
• Regulatory delays if excipients lack clear safety profiles.

Summary of formulation strategies

Strategy	Purpose	Examples
Taste masking	Improve patient compliance	Flavored coatings, sweeteners like sorbitol
Controlled release	Extend drug action	Hydroxypropyl methylcellulose coatings
Rapid disintegration	Enhance onset	Croscarmellose sodium
Stability enhancement	Prevent degradation	Antioxidant excipients like ascorbic acid

Conclusion

Formulating 24 Hour Allergy with the appropriate excipients enhances product efficacy, safety, and consumer appeal. The market favors innovative excipient approaches that respond to regulatory demands and consumer preferences, presenting opportunities for differentiated formulations.

---

Key Takeaways

• Excipient selection in 24 Hour Allergy formulations centers on compatibility, stability, and patient experience.
• Market trends favor natural, multifunctional, and safety-verified excipients.
• Regulatory compliance shapes excipient choice, especially for sensitive populations.
• Innovation in excipient technology offers competitive advantages.
• Cost, safety, and regulatory risks must be managed in excipient strategy.

FAQs

1. How does excipient choice impact the shelf life of allergy medications?
Excipients influence drug stability by either protecting active ingredients from degradation or causing instability if incompatible. Proper selection extends shelf life and maintains efficacy.

2. Are natural excipients preferable for allergy formulations?
Natural excipients meet consumer demand for "clean-label" products and may reduce allergic reactions. However, they require thorough stability and safety evaluation.

3. What excipients are critical for pediatric allergy medications?
Taste masking agents, dispersible excipients, and safety-verified preservatives are crucial. Compatibility with young patients' sensitivities guides selection.

4. How do regulatory agencies influence excipient innovation?
Agencies require detailed safety profiles and restrict the use of novel excipients unless thoroughly evaluated, limiting rapid adoption but encouraging safety-focused innovation.

5. What cost considerations affect excipient strategy?
High-quality or proprietary excipients increase formulation costs but may improve safety and efficacy. Balancing cost and benefit is essential for competitive pricing.

---

References

1. US Food and Drug Administration (FDA). (2020). Guidance for Industry: Excipients in Drug Products.
2. European Medicines Agency (EMA). (2019). Guideline on excipients in the label and package leaflet of medicinal products.

[1] FDA. (2020). Guidance for Industry: Excipients in Drug Products.
[2] EMA. (2019). Guideline on excipients in the label and package leaflet of medicinal products.